• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于非天然氨基酸点击化学的技术,用于将多糖位点特异性缀合至作为载体和疫苗抗原的细菌蛋白。

Non-Native Amino Acid Click Chemistry-Based Technology for Site-Specific Polysaccharide Conjugation to a Bacterial Protein Serving as Both Carrier and Vaccine Antigen.

作者信息

Kapoor Neeraj, Uchiyama Satoshi, Pill Lucy, Bautista Leslie, Sedra Angie, Yin Lu, Regan Maritoni, Chu Ellen, Rabara Taylor, Wong Melissa, Davey Peter, Fairman Jeff, Nizet Victor

机构信息

Vaxcyte, Inc., 825 Industrial Road, Suite 300, San Carlos, California 94070, United States.

Division of Host-Microbe Systems and Therapeutics, Department of Pediatrics and Skaggs School of Pharmacy and Pharmaceutical Sciences, UC San Diego, 9500 Gilman Drive Mail Code 0760, La Jolla, California 92093, United States.

出版信息

ACS Omega. 2022 Jul 11;7(28):24111-24120. doi: 10.1021/acsomega.1c07360. eCollection 2022 Jul 19.

DOI:10.1021/acsomega.1c07360
PMID:35874267
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9301713/
Abstract

Surface-expressed bacterial polysaccharides are important vaccine antigens but must be conjugated to a carrier protein for efficient antigen presentation and development of strong memory B cell and antibody responses, especially in young children. The commonly used protein carriers include tetanus toxoid (TT), diphtheria toxoid (DT), and its derivative CRM197, but carrier-induced epitopic suppression and bystander interference may limit the expanded use of the same carriers in the pediatric immunization schedule. Recent efforts to develop a vaccine against the major human pathogen group A (GAS) have sought to combine two promising vaccine antigens-the universally conserved group A cell wall carbohydrate (GAC) with the secreted toxin antigen streptolysin O (SLO) as a protein carrier; however, standard reductive amination procedures appeared to destroy function epitopes of the protein, markedly diminishing functional antibody responses. Here, we couple a cell-free protein synthesis (CFPS) platform, allowing the incorporation of non-natural amino acids into a C-terminally truncated SLO toxoid for the precise conjugation to the polyrhamnose backbone of GAC. The combined immunogen generated functional antibodies against both conserved GAS virulence factors and provided protection against systemic GAS challenges. CFPS may represent a scalable method for generating pathogen-specific carrier proteins for multivalent subunit vaccine development.

摘要

表面表达的细菌多糖是重要的疫苗抗原,但必须与载体蛋白偶联,以实现有效的抗原呈递,并引发强烈的记忆B细胞和抗体反应,尤其是在幼儿中。常用的蛋白质载体包括破伤风类毒素(TT)、白喉类毒素(DT)及其衍生物CRM197,但载体诱导的表位抑制和旁观者干扰可能会限制同一载体在儿童免疫计划中的广泛使用。最近,针对主要人类病原体A组链球菌(GAS)开发疫苗的努力试图将两种有前景的疫苗抗原结合起来——普遍保守的A组细胞壁碳水化合物(GAC)与分泌的毒素抗原链球菌溶血素O(SLO)作为蛋白质载体;然而,标准的还原胺化程序似乎破坏了蛋白质的功能表位,显著降低了功能性抗体反应。在这里,我们结合了一个无细胞蛋白质合成(CFPS)平台,允许将非天然氨基酸掺入C末端截短的SLO类毒素中,以便与GAC的聚鼠李糖主链精确偶联。这种组合免疫原产生了针对两种保守的GAS毒力因子的功能性抗体,并提供了针对全身性GAS攻击的保护。CFPS可能代表了一种可扩展的方法,用于为多价亚单位疫苗开发生成病原体特异性载体蛋白。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/633a/9301713/66ed67d9851a/ao1c07360_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/633a/9301713/75301a91f65f/ao1c07360_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/633a/9301713/cc99d535bbdc/ao1c07360_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/633a/9301713/d82fe641f5c2/ao1c07360_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/633a/9301713/66ed67d9851a/ao1c07360_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/633a/9301713/75301a91f65f/ao1c07360_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/633a/9301713/cc99d535bbdc/ao1c07360_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/633a/9301713/d82fe641f5c2/ao1c07360_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/633a/9301713/66ed67d9851a/ao1c07360_0005.jpg

相似文献

1
Non-Native Amino Acid Click Chemistry-Based Technology for Site-Specific Polysaccharide Conjugation to a Bacterial Protein Serving as Both Carrier and Vaccine Antigen.基于非天然氨基酸点击化学的技术,用于将多糖位点特异性缀合至作为载体和疫苗抗原的细菌蛋白。
ACS Omega. 2022 Jul 11;7(28):24111-24120. doi: 10.1021/acsomega.1c07360. eCollection 2022 Jul 19.
2
Carrier priming with CRM 197 or diphtheria toxoid has a different impact on the immunogenicity of the respective glycoconjugates: biophysical and immunochemical interpretation.CRM197 或白喉类毒素载体预致敏对相应糖结合物的免疫原性有不同影响:生物物理和免疫化学解释。
Vaccine. 2015 Jan 3;33(2):314-20. doi: 10.1016/j.vaccine.2014.11.026. Epub 2014 Nov 22.
3
Non-clinical immunological comparison of a Next-Generation 24-valent pneumococcal conjugate vaccine (VAX-24) using site-specific carrier protein conjugation to the current standard of care (PCV13 and PPV23).下一代 24 价肺炎球菌结合疫苗(VAX-24)与当前标准治疗方法(PCV13 和 PPV23)的非临床免疫比较,使用了基于特定部位的载体蛋白偶联技术。
Vaccine. 2021 May 27;39(23):3197-3206. doi: 10.1016/j.vaccine.2021.03.070. Epub 2021 May 6.
4
A Novel O-Polysaccharide-IpaB Conjugate Vaccine Elicits Robust Antibody Responses and Confers Protection against Multiple Serotypes.一种新型 O-多糖-IpaB 缀合疫苗可诱导强烈的抗体应答,并针对多种血清型提供保护。
mSphere. 2023 Jun 22;8(3):e0001923. doi: 10.1128/msphere.00019-23. Epub 2023 Apr 5.
5
Effect of Tdap upon antibody response to meningococcal polysaccharide when administered before, with or after the quadrivalent meningococcal TT-conjugate vaccine (coadministered with the 13-valent pneumococcal CRM197-conjugate vaccine) in adult Hajj pilgrims: A randomised controlled trial.Tdap 对在接种四价脑膜炎球菌结合疫苗(与 13 价肺炎球菌 CRM197 结合疫苗联合接种)前、同时或之后接种的成人朝觐者对脑膜炎球菌多糖的抗体应答的影响:一项随机对照试验。
Vaccine. 2018 Jul 5;36(29):4375-4382. doi: 10.1016/j.vaccine.2018.04.033. Epub 2018 Jun 5.
6
Comparison of CRM197, diphtheria toxoid and tetanus toxoid as protein carriers for meningococcal glycoconjugate vaccines.CRM197、白喉类毒素和破伤风类毒素作为脑膜炎球菌糖结合疫苗的蛋白载体的比较。
Vaccine. 2013 Oct 1;31(42):4827-33. doi: 10.1016/j.vaccine.2013.07.078. Epub 2013 Aug 17.
7
Rational Design of a Glycoconjugate Vaccine against Group A .针对 A 群链球菌的糖缀合物疫苗的合理设计
Int J Mol Sci. 2020 Nov 13;21(22):8558. doi: 10.3390/ijms21228558.
8
Modulation of carrier-induced epitopic suppression by Bordetella pertussis components and muramyl peptide.百日咳博德特氏菌成分和胞壁酰肽对载体诱导的表位抑制的调节作用。
Cell Immunol. 1987 Jun;107(1):40-51. doi: 10.1016/0008-8749(87)90264-4.
9
Development of a bivalent conjugate vaccine candidate against rotaviral diarrhea and tuberculosis using polysaccharide from Mycobacterium tuberculosis conjugated to ΔVP8* protein from rotavirus.利用结核分枝杆菌多糖与轮状病毒 ΔVP8* 蛋白偶联,研制针对轮状病毒腹泻和结核病的二价结合疫苗候选物。
Vaccine. 2021 Oct 29;39(45):6644-6652. doi: 10.1016/j.vaccine.2021.09.067. Epub 2021 Oct 9.
10
Testing a Recombinant Form of Tetanus Toxoid as a Carrier Protein for Glycoconjugate Vaccines.测试破伤风类毒素的重组形式作为糖共轭疫苗的载体蛋白。
Vaccines (Basel). 2023 Nov 28;11(12):1770. doi: 10.3390/vaccines11121770.

引用本文的文献

1
Engaging Broader Stakeholders to Accelerate Group A Vaccine Development.吸引更广泛的利益相关者以加速A群疫苗的研发。
Vaccines (Basel). 2025 Jul 7;13(7):734. doi: 10.3390/vaccines13070734.
2
Breaking barriers: Smart vaccine platforms for cancer immunomodulation.突破障碍:用于癌症免疫调节的智能疫苗平台
Cancer Commun (Lond). 2025 May;45(5):529-571. doi: 10.1002/cac2.70002. Epub 2025 Feb 3.
3
Recombinant production platform for Group A Streptococcus glycoconjugate vaccines.A群链球菌糖结合疫苗的重组生产平台

本文引用的文献

1
Polysaccharide peptide conjugates: Chemistry, properties and applications.多糖肽缀合物:化学、性质及应用
Carbohydr Polym. 2022 Mar 15;280:118875. doi: 10.1016/j.carbpol.2021.118875. Epub 2021 Nov 9.
2
Immunobiology of the Classical Lancefield Group A Streptococcal Carbohydrate Antigen.经典 A 组链球菌碳水化合物抗原的免疫生物学。
Infect Immun. 2021 Nov 16;89(12):e0029221. doi: 10.1128/IAI.00292-21. Epub 2021 Sep 20.
3
Streptolysins are the primary inflammasome activators in macrophages during Streptococcus pyogenes infection.
NPJ Vaccines. 2025 Jan 22;10(1):16. doi: 10.1038/s41541-025-01068-2.
4
Circumventing the Impossible: Cell-Free Synthesis of Protein Toxins for Medical and Diagnostic Applications.突破不可能:用于医学和诊断应用的无细胞蛋白质毒素合成
Int J Mol Sci. 2024 Dec 11;25(24):13293. doi: 10.3390/ijms252413293.
5
The intricate pathogenicity of Group A : A comprehensive update.A 组链球菌的复杂致病机制:全面更新。
Virulence. 2024 Dec;15(1):2412745. doi: 10.1080/21505594.2024.2412745. Epub 2024 Nov 5.
6
Efficacy of Alum-Adjuvanted Peptide and Carbohydrate Conjugate Vaccine Candidates against Group A Pharyngeal Infection in a Non-Human Primate Model.明矾佐剂肽与碳水化合物结合疫苗候选物在非人灵长类动物模型中抗A组咽部感染的疗效
Vaccines (Basel). 2024 Apr 4;12(4):382. doi: 10.3390/vaccines12040382.
7
The Group A Streptococcal Vaccine Candidate VAX-A1 Protects against Group B Infection via Cross-Reactive IgG Targeting Virulence Factor C5a Peptidase.A组链球菌候选疫苗VAX-A1通过靶向毒力因子C5a肽酶的交叉反应性IgG预防B组感染。
Vaccines (Basel). 2023 Dec 3;11(12):1811. doi: 10.3390/vaccines11121811.
8
Progress towards a glycoconjugate vaccine against Group A Streptococcus.抗A群链球菌糖缀合物疫苗的研究进展。
NPJ Vaccines. 2023 Mar 28;8(1):48. doi: 10.1038/s41541-023-00639-5.
9
Carriers and Antigens: New Developments in Glycoconjugate Vaccines.载体与抗原:糖缀合物疫苗的新进展
Vaccines (Basel). 2023 Jan 19;11(2):219. doi: 10.3390/vaccines11020219.
10
A Review of Protein- and Peptide-Based Chemical Conjugates: Past, Present, and Future.基于蛋白质和肽的化学偶联物综述:过去、现在与未来
Pharmaceutics. 2023 Feb 10;15(2):600. doi: 10.3390/pharmaceutics15020600.
链球菌溶血素是化脓性链球菌感染期间巨噬细胞中主要的炎症小体激活物。
Immunol Cell Biol. 2021 Nov;99(10):1040-1052. doi: 10.1111/imcb.12499. Epub 2021 Sep 18.
4
Non-clinical immunological comparison of a Next-Generation 24-valent pneumococcal conjugate vaccine (VAX-24) using site-specific carrier protein conjugation to the current standard of care (PCV13 and PPV23).下一代 24 价肺炎球菌结合疫苗(VAX-24)与当前标准治疗方法(PCV13 和 PPV23)的非临床免疫比较,使用了基于特定部位的载体蛋白偶联技术。
Vaccine. 2021 May 27;39(23):3197-3206. doi: 10.1016/j.vaccine.2021.03.070. Epub 2021 May 6.
5
Recent advances on smart glycoconjugate vaccines in infections and cancer.智能糖缀合物疫苗在感染和癌症中的最新进展。
FEBS J. 2022 Jul;289(14):4251-4303. doi: 10.1111/febs.15909. Epub 2021 Jun 1.
6
Immunogenicity Assessment of Cell Wall Carbohydrates of Group A via Self-Adjuvanted Glyco-lipopeptides.通过自佐剂糖脂肽评估 A 组菌细胞壁碳水化合物的免疫原性。
ACS Infect Dis. 2021 Feb 12;7(2):390-405. doi: 10.1021/acsinfecdis.0c00722. Epub 2021 Feb 3.
7
Glycoconjugations of Biomolecules by Chemical Methods.通过化学方法进行生物分子的糖基化修饰
Front Chem. 2020 Nov 4;8:570185. doi: 10.3389/fchem.2020.570185. eCollection 2020.
8
Rational Design of a Glycoconjugate Vaccine against Group A .针对 A 群链球菌的糖缀合物疫苗的合理设计
Int J Mol Sci. 2020 Nov 13;21(22):8558. doi: 10.3390/ijms21228558.
9
Gold nanoparticles morphology does not affect the multivalent presentation and antibody recognition of Group A Streptococcus synthetic oligorhamnans.金纳米颗粒的形态不会影响 A 组链球菌合成寡糖的多价呈现和抗体识别。
Bioorg Chem. 2020 Jun;99:103815. doi: 10.1016/j.bioorg.2020.103815. Epub 2020 Apr 3.
10
Vaccine-Induced Th1-Type Response Protects against Invasive Group A Infection in the Absence of Opsonizing Antibodies.疫苗诱导的 Th1 型反应可在没有调理抗体的情况下预防侵袭性 A 组感染。
mBio. 2020 Mar 10;11(2):e00122-20. doi: 10.1128/mBio.00122-20.